{"id":390716,"date":"2018-03-29T00:00:00","date_gmt":"2018-03-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0017-2018-biopharma-rheumatoid-arthritis-unmet-need-tnf-alpha-refractory-us-eu-2018\/"},"modified":"2026-04-30T23:44:36","modified_gmt":"2026-04-30T23:44:36","slug":"unneim0017-2018-biopharma-rheumatoid-arthritis-unmet-need-tnf-alpha-refractory-us-eu-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0017-2018-biopharma-rheumatoid-arthritis-unmet-need-tnf-alpha-refractory-us-eu-2018\/","title":{"rendered":"Rheumatoid Arthritis | Unmet Need | TNF-alpha Refractory | US\/EU | 2018"},"content":{"rendered":"<p>Rheumatoid arthritis (<abbr title=\"rheumatoid arthritis\">RA<\/abbr>) treatment typically begins with one or more conventional <abbr title=\"disease-modifying antirheumatic drug\">DMARD<\/abbr>s, followed by a first-line biologic, usually a <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitor. Patients refractory to one or more <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors are then given a non-<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-targeted therapy (biologics\/<abbr title=\"Janus activated kinase\">Jak<\/abbr> inhibitors). Although the <abbr title=\"rheumatoid arthritis\">RA<\/abbr> market is generally considered to have multiple efficacious and relatively safe agents, patients refractory to <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors have limited options even with the recent entry of newer agents (<abbr title=\"interleukin\">IL<\/abbr>-6 inhibitors, <abbr title=\"Janus activated kinase\">Jak<\/abbr> inhibitors). For the <abbr title=\"tumor necrosis factor-alpha inhibitor\">TNFi<\/abbr>-refractory <abbr title=\"rheumatoid arthritis\">RA<\/abbr> subpopulation, an unmet need exists for agents able to demonstrate greater efficacy in reducing signs and symptoms of disease and inducing clinical remission. In addition, the serious (although rare) safety signals associated with most targeted therapies remains a concern when physicians are making prescribing decisions. With quantitative insight into U.S. and European rheumatologist assessment of the unmet need in <abbr title=\"tumor necrosis factor-alpha inhibitor\">TNFi<\/abbr>-refractory <abbr title=\"rheumatoid arthritis\">RA<\/abbr>, we analyze remaining commercial opportunities and discuss how emerging therapies may capitalize on these opportunities. The emerging <abbr title=\"Janus activated kinase\">Jak<\/abbr> inhibitor upadacitinib has shown promising efficacy and is analyzed against marketed agents in the same class, Xeljanz and Olumiant, with regard to physician preference and prescribing likelihood.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for <abbr title=\"tumor necrosis factor-alpha inhibitor\">TNFi<\/abbr>-refractory <abbr title=\"rheumatoid arthritis\">RA<\/abbr>?<\/li>\n<li>What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for <abbr title=\"tumor necrosis factor-alpha inhibitor\">TNFi<\/abbr>-refractory <abbr title=\"rheumatoid arthritis\">RA<\/abbr>?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in <abbr title=\"tumor necrosis factor-alpha inhibitor\">TNFi<\/abbr>-refractory <abbr title=\"rheumatoid arthritis\">RA<\/abbr>?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists for a hypothetical new drug targeting <abbr title=\"tumor necrosis factor-alpha inhibitor\">TNFi<\/abbr>-refractory <abbr title=\"rheumatoid arthritis\">RA<\/abbr>?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany.<\/p>\n<p><strong>Primary research: <\/strong>Survey of 61 U.S. and 30 European rheumatologists fielded in January 2018.<\/p>\n<p><strong>Key companies:<\/strong> AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Pfizer, Regeneron, Roche, Sanofi.<\/p>\n<p><strong>Key drugs:<\/strong> Humira, Remicade, Rituxan\/MabThera, Orencia, Actemra\/RoActemra, Xeljanz, Olumiant<\/p>\n","protected":false},"template":"","class_list":["post-390716","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390716\/revisions"}],"predecessor-version":[{"id":393840,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390716\/revisions\/393840"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}